Andreessen Horowitz

Orbital Therapeutics is focused on advancing global health through the development of RNA-based medicines aimed at treating various human diseases. The company is building an innovative platform that integrates established and emerging technologies, delivery mechanisms, and data analytics to create a diverse portfolio of therapeutics. Their efforts encompass a wide range of applications, including vaccines, immunomodulation, protein replacement, and regenerative medicine. By harnessing the full potential of RNA technology, Orbital Therapeutics seeks to provide patients with modern treatment options that were previously unavailable, thus enhancing the efficacy and accessibility of medical therapies.

Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, focused on developing an automated platform for the production and characterization of antibodies. Founded in 2019, the company utilizes an AI-guided protein therapeutic platform that combines a wet laboratory with advanced machine learning techniques. This integrated approach enables the design of antibodies and other therapeutic proteins with enhanced biophysical properties and complex functions. BigHat Biosciences aims to create safer and more effective treatments for patients facing significant health challenges by leveraging its innovative capabilities in antibody engineering and biotherapeutic design.

Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.

Octant Bio is focused on advancing health and treating complex diseases through innovative synthetic technology. The company utilizes a combination of synthetic biology, genome engineering, next-generation sequencing, and computational methods to assess the activity of numerous receptor pathways within human cells. This approach allows for the development of multi-targeted small molecule drug leads by leveraging machine learning to engineer compounds that interact with multiple receptors. By generating extensive multi-receptor pathway data, Octant Bio aims to enhance rational drug design and uncover new therapeutic possibilities. Founded in 2017 and based in Los Angeles, California, Octant Bio is dedicated to transforming the landscape of drug discovery and development.

Octant Bio is focused on advancing health and treating complex diseases through innovative synthetic technology. The company utilizes a combination of synthetic biology, genome engineering, next-generation sequencing, and computational methods to assess the activity of numerous receptor pathways within human cells. This approach allows for the development of multi-targeted small molecule drug leads by leveraging machine learning to engineer compounds that interact with multiple receptors. By generating extensive multi-receptor pathway data, Octant Bio aims to enhance rational drug design and uncover new therapeutic possibilities. Founded in 2017 and based in Los Angeles, California, Octant Bio is dedicated to transforming the landscape of drug discovery and development.

Nansen Limited is a company that develops a blockchain analytics platform designed to assist cryptocurrency investors in identifying opportunities and managing their portfolios. Founded in 2019 and based in Wan Chai, Hong Kong, Nansen combines on-chain data with a comprehensive database to enhance the analysis of cryptocurrency transactions. Its platform provides features such as wallet labeling, transaction tracing, and real-time alerts, enabling users to conduct due diligence and make informed investment decisions. By enriching on-chain data, Nansen aims to facilitate more efficient operations for investors in the rapidly evolving cryptocurrency market.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, focused on developing an automated platform for the production and characterization of antibodies. Founded in 2019, the company utilizes an AI-guided protein therapeutic platform that combines a wet laboratory with advanced machine learning techniques. This integrated approach enables the design of antibodies and other therapeutic proteins with enhanced biophysical properties and complex functions. BigHat Biosciences aims to create safer and more effective treatments for patients facing significant health challenges by leveraging its innovative capabilities in antibody engineering and biotherapeutic design.

Octant Bio is focused on advancing health and treating complex diseases through innovative synthetic technology. The company utilizes a combination of synthetic biology, genome engineering, next-generation sequencing, and computational methods to assess the activity of numerous receptor pathways within human cells. This approach allows for the development of multi-targeted small molecule drug leads by leveraging machine learning to engineer compounds that interact with multiple receptors. By generating extensive multi-receptor pathway data, Octant Bio aims to enhance rational drug design and uncover new therapeutic possibilities. Founded in 2017 and based in Los Angeles, California, Octant Bio is dedicated to transforming the landscape of drug discovery and development.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

Octant Bio is focused on advancing health and treating complex diseases through innovative synthetic technology. The company utilizes a combination of synthetic biology, genome engineering, next-generation sequencing, and computational methods to assess the activity of numerous receptor pathways within human cells. This approach allows for the development of multi-targeted small molecule drug leads by leveraging machine learning to engineer compounds that interact with multiple receptors. By generating extensive multi-receptor pathway data, Octant Bio aims to enhance rational drug design and uncover new therapeutic possibilities. Founded in 2017 and based in Los Angeles, California, Octant Bio is dedicated to transforming the landscape of drug discovery and development.

Their academia-leading research was the initial component of our expanding portfolio of AI technologies. They are combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in a molecular generation and property prediction. The company was founded in 2019 and based in South San Francisco, California.

Asimov, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in designing and developing genetically engineered therapeutics. The company utilizes a platform for molecular manufacturing, which incorporates machine-learning algorithms to connect large-scale biological datasets with mechanistic models. Asimov programs living cells with genetic circuits, enabling the creation of innovative biotechnologies in partnership with its customers. Their capabilities include the manufacturing of protein biologics, viral vectors, and cell and gene therapies. Founded in 2017, Asimov leverages a combination of computer-aided design, artificial intelligence, and synthetic biology to advance its mission.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

At Shield, we’re ensuring that antibiotic resistance doesn’t become more deadly than cancer. In 2050 more people will be dying of antibiotic resistant pathogens than cancer. Infections that were once treatable with a simple oral antibiotics are now requiring complex, painful treatments and resulting in serious health complications for patients. Gonorrhea is one such infection, having become resistant to over 10 different antibiotics, they have only one treatment that is still effective and resistance to this has already begun to emerge. With 820,000 new infections every year in the US, antibiotic resistance will spread quickly, which is why the CDC has resistant gonorrhea at an urgent threat level, the highest level available. Shield's novel genomic testing platform enables STI clinics to identify the antibiotic resistant strains of gonorrhea and other pathogens that their patients have, so they can select the correct antibiotics and halt the spread of antibiotic resistance.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Halo Neuroscience is a neurotechnology company based in San Francisco that focuses on enhancing human performance through innovative systems. Since its incorporation in 2013, the company has developed its flagship product, Halo Sport, which employs Neuropriming technology. This technology involves delivering electrical stimulation during physical training to enhance the brain's learning capacity, a state referred to as "hyperplasticity." By improving the connections between the brain and muscles, Halo Sport aims to accelerate skill acquisition and strength development, particularly for elite athletes. Through its advancements in neurotechnology, Halo Neuroscience seeks to help individuals maximize their potential in various performance domains.

Udacity is an online learning platform that specializes in providing educational programs in fields such as artificial intelligence, machine learning, data science, robotics, and cloud computing. Founded in 2011 by David Stavens, Mike Sokolsky, and Sebastian Thrun, the company offers a variety of nanodegree programs designed to equip students with skills that are highly sought after by employers. These programs include training for roles such as web developer, data analyst, and machine learning engineer. Udacity aims to make education more accessible and affordable, thereby helping individuals enhance their career prospects. The platform evolved from free computer science classes offered at Stanford University and has since attracted millions of users. Udacity collaborates with technology companies to ensure that its curriculum aligns with industry demands, thereby preparing learners for the most in-demand tech positions. While the company has not yet turned a profit, it has experienced significant growth and investment, being valued at over $1 billion.

Udacity is an online learning platform that specializes in providing educational programs in fields such as artificial intelligence, machine learning, data science, robotics, and cloud computing. Founded in 2011 by David Stavens, Mike Sokolsky, and Sebastian Thrun, the company offers a variety of nanodegree programs designed to equip students with skills that are highly sought after by employers. These programs include training for roles such as web developer, data analyst, and machine learning engineer. Udacity aims to make education more accessible and affordable, thereby helping individuals enhance their career prospects. The platform evolved from free computer science classes offered at Stanford University and has since attracted millions of users. Udacity collaborates with technology companies to ensure that its curriculum aligns with industry demands, thereby preparing learners for the most in-demand tech positions. While the company has not yet turned a profit, it has experienced significant growth and investment, being valued at over $1 billion.

Udacity is an online learning platform that specializes in providing educational programs in fields such as artificial intelligence, machine learning, data science, robotics, and cloud computing. Founded in 2011 by David Stavens, Mike Sokolsky, and Sebastian Thrun, the company offers a variety of nanodegree programs designed to equip students with skills that are highly sought after by employers. These programs include training for roles such as web developer, data analyst, and machine learning engineer. Udacity aims to make education more accessible and affordable, thereby helping individuals enhance their career prospects. The platform evolved from free computer science classes offered at Stanford University and has since attracted millions of users. Udacity collaborates with technology companies to ensure that its curriculum aligns with industry demands, thereby preparing learners for the most in-demand tech positions. While the company has not yet turned a profit, it has experienced significant growth and investment, being valued at over $1 billion.